Fellowship · Rochester, NY
Sponsored by University of Rochester Medicine
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Nature medicine · 2025 · 143 citations · Emma Ciafaloni, Aravindhan Veerapandiyan
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
The Lancet. Neurology · 2025 · 76 citations · Constantine Farmakidis
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
The New England journal of medicine · 2025 · 51 citations · Emma Ciafaloni
Leveraging deep single-soma RNA sequencing to explore the neural basis of human somatosensation.
Nature neuroscience · 2024 · 76 citations · James Wymer
Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
JAMA · 2022 · 116 citations · Emma Ciafaloni, Jeffrey Statland
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
Neurology · 2022 · 99 citations · Emma Ciafaloni
Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.
EBioMedicine · 2024 · 45 citations · Jeffrey Statland
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve · 2021 · 141 citations · James Wymer